Figure 1. Recruitment to the ADAPT programme.
Figure 2. The basic demographics for the 1,203 patients who have undergone at least one baseline assessment since the start of the registry in 1996 is shown just for the PiZZ and SZ genotypes.
Figure 3. Bronchodilator reversibility to combined beta2agonist and anticholinergic agent is shown for the first 390 patients (PiZZ) as the proportion showing each% increase in FEV1.
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
